Your session is about to expire
← Back to Search
Hu3F8 + GM-CSF + Isotretinoin for Neuroblastoma
Study Summary
This trial is testing the effects of a drug called Humanized 3F8 (Hu3F8) when used in combination with another drug called granulocyte-macrophage colony stimulating factor (GM-CSF). The trial is testing to see if this combination can prevent neuroblastoma from growing, but it could also cause side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is in its first complete or very good partial response.I do not have severe organ problems, except possible hearing loss or blood issues.I do not have a severe infection that is threatening my life.My neuroblastoma diagnosis is confirmed by specific tests and high urine catecholamine levels.My neuroblastoma is high-risk, either due to MYCN amplification or being over 18 months with stage 4.
- Group 1: Hu3F8/GM-CSF Plus Isotretinoin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What therapeutic applications does Hu3F8 typically serve?
"Hu3F8 is typically prescribed for rosacea, but can also be administered to patients with conditions such as osteoporosis, neuroblastoma (nb), and refractory acne vulgaris."
Are there any vacancies open for participants in this research?
"Unfortunately, no further participants are being accepted for this trial. It was initially advertised on January 23rd 2017 and the last update occured on July 1st 2022. On the other hand, there exist 161 clinical studies recruiting patients with neuroblastoma and 22 trials requesting Hu3F8 volunteers."
What risk factors are associated with Hu3F8 administration?
"Analysis from Power teams rates Hu3F8's safety as a 2, considering the lack of clinical data regarding efficacy and only some evidence for safety."
Has Hu3F8 been studied in other research projects?
"At the moment, 22 Hu3F8 studies are in progress; 4 of which have entered Phase 3. Sioux Falls is home to most of those trials but 723 other sites are being used as well."
What is the upper-limit of participants in this medical exploration?
"Unfortunately, this research is not open to any new participants at the moment. It first appeared on January 23rd 2017 and was last amended on July 1st 2022. However, 161 studies related to neuroblastoma are currently recruiting patients along with 22 trials for Hu3F8 that need applicants."
Share this study with friends
Copy Link
Messenger